

## S 3792

### Preserve Access to Affordable Generics and Biosimilars Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Dec 19, 2018

**Current Status:** Read twice and referred to the Committee on the Judiciary.

**Latest Action:** Read twice and referred to the Committee on the Judiciary. (Dec 19, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/3792>

## Sponsor

**Name:** Sen. Klobuchar, Amy [D-MN]

**Party:** Democratic • **State:** MN • **Chamber:** Senate

## Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Grassley, Chuck [R-IA]	R · IA		Dec 19, 2018

## Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	Dec 19, 2018

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
115 S 124	Related bill	Jan 12, 2017: Read twice and referred to the Committee on the Judiciary.

## Summary (as of Dec 19, 2018)

### Preserve Access to Affordable Generics and Biosimilars Act

This bill amends the Federal Trade Commission Act to authorize the Federal Trade Commission to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exceptions, is presumed to have anticompetitive effects and violates this bill if the filer of an abbreviated new drug (generic) application or a biosimilar biological product application: (1) receives anything of value; and (2) agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar biological product for any period of time.

## **Actions Timeline**

---

- **Dec 19, 2018:** Introduced in Senate
- **Dec 19, 2018:** Read twice and referred to the Committee on the Judiciary.